Format

Send to

Choose Destination
Am J Psychiatry. 2018 Jan 1;175(1):15-27. doi: 10.1176/appi.ajp.2017.17030283. Epub 2017 Oct 3.

Psychiatric Genomics: An Update and an Agenda.

Author information

1
From the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm; the Departments of Genetics, Psychiatry, and Nutrition, University of North Carolina, Chapel Hill, N.C.; the Department of Psychiatry, Washington University School of Medicine, St Louis; the Norwegian Centre for Mental Disorders Research (NORMENT), K.G. Jebsen Centre for Research on Neuropsychiatric Disorders, University of Oslo and Oslo University Hospital, Oslo; the Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Aarhus, Denmark; the Center for Integrative Sequencing (iSEQ), Aarhus University, Aarhus, Denmark; the Department of Biomedicine-Human Genetics, Aarhus University, Aarhus, Denmark; the Institute of Psychiatry, Psychology and Neuroscience, MRC Social, Genetic and Developmental Psychiatry Centre, King's College London, London; the National Institute for Health Research Biomedical Research Centre, South London and Maudsley National Health Service Trust, London; the Division of Medical Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland; the Institute of Human Genetics, University of Bonn, Bonn, Germany; the Department of Genomics, Life and Brain Center, Bonn, Germany; the Institute of Neuroscience and Medicine, Juelich, Germany; the Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis; the Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, N.Y.; the Department of Psychiatry, Yale University, New Haven, Conn.; the Department of Psychiatry and the Genetics Institute, University of Florida, Gainesville; the Department of Psychiatry, University of California-San Diego, La Jolla, Calif., the Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, and the Department of Psychiatry, Massachusetts General Hospital, Boston; the Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Mass.; and the MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, U.K.

Abstract

The Psychiatric Genomics Consortium (PGC) is the largest consortium in the history of psychiatry. This global effort is dedicated to rapid progress and open science, and in the past decade it has delivered an increasing flow of new knowledge about the fundamental basis of common psychiatric disorders. The PGC has recently commenced a program of research designed to deliver "actionable" findings-genomic results that 1) reveal fundamental biology, 2) inform clinical practice, and 3) deliver new therapeutic targets. The central idea of the PGC is to convert the family history risk factor into biologically, clinically, and therapeutically meaningful insights. The emerging findings suggest that we are entering a phase of accelerated genetic discovery for multiple psychiatric disorders. These findings are likely to elucidate the genetic portions of these truly complex traits, and this knowledge can then be mined for its relevance for improved therapeutics and its impact on psychiatric practice within a precision medicine framework. [AJP at 175: Remembering Our Past As We Envision Our Future November 1946: The Genetic Theory of Schizophrenia Franz Kallmann's influential twin study of schizophrenia in 691 twin pairs was the largest in the field for nearly four decades. (Am J Psychiatry 1946; 103:309-322 )].

KEYWORDS:

Biological Markers; Genetics

PMID:
28969442
PMCID:
PMC5756100
DOI:
10.1176/appi.ajp.2017.17030283
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center